Breast cancer risk cut by 35% in new clinical trial
Trodelvy in combination with Merck's blockbuster immunotherapy Keytruda lowered the risk of an aggressive type of breast cancer worsening by 35% when used as an initial treatment, according to results of a large trial presented on Saturday.
The data is likely to change how patients are treated following a diagnosis for advanced triple-negative breast cancer, one expert said.
After a median follow-up of 14 months, patients treated with Trodelvy, a so-called antibody-drug conjugate, and Keytruda went 11.2 months without their cancer progressing, a measure known as progress-free survival. That compared with PFS of 7.8 months for those given the standard treatment of chemotherapy and Keytruda, researchers said.
Advertisement
3 Trodelvy, in combination with Merck's immunotherapy Keytruda, lowered the risk of an aggressive type of breast cancer worsening by 35% when used as an initial treatment, according to new results.
REUTERS
Patients given the Trodelvy/Keytruda combination responded to the treatment for a median of 16.5 months, compared with 9.2 months for the chemo group, according to full results of the study presented at the American Society of Clinical Oncology scientific meeting in Chicago. The researchers said patients are still being followed to see if the regimen has an impact on overall survival.
Gilead previously said the Phase 3 study in 443 patients with advanced triple-negative breast cancer whose tumors express PD-L1 – the protein targeted by drugs like Keytruda – had met its goal.
Advertisement
The findings suggest that the combination of Trodelvy and Keytruda 'will likely become a new front-line standard of care in this setting,' Dr. Jane Lowe Meisel, co-director of breast oncology at Emory University School of Medicine and a designated ASCO expert, said in a statement.
ASCO estimates that about 10% of breast cancers in the United States are triple-negative.
3 Patients given the Trodelvy/Keytruda combination responded to the treatment for a median of 16.5 months, compared with 9.2 months for the chemo group, according to the results.
Peakstock – stock.adobe.com
That tends to be more difficult to treat than hormone-sensitive subtypes, because it does not have the common biomarkers used to guide treatment, the tumors are often larger, and the recurrence rate is high.
Advertisement
The medical group said that about 40% of triple-negative breast cancers are also PD-L1 positive, making them candidates for Keytruda.
Antibody-drug conjugates like Trodelvy are designed to deliver an anti-cancer drug more precisely to malignant cells, causing less damage to healthy cells than chemotherapy.
3 Gilead is also conducting several other Trodelvy studies, including a trial of the drug as an initial treatment for triple-negative breast cancer patients who do not express PD-L1.
REUTERS
Serious side effects for Trodelvy included neutropenia, a condition caused by cancer treatments that lower levels of infection-fighting white blood cells, reported in 43% of patients, and diarrhea in 10%. In the chemotherapy group, the incidence of neutropenia was 45%, while 16% of patients had anemia and 14% had low blood platelet counts.
Advertisement
Trodelvy is already approved for patients with advanced triple-negative breast cancer who had two or more prior therapies, and for previously treated hormone-receptor-positive, HER2-negative metastatic breast cancer.
Gilead is conducting several other Trodelvy studies, including a trial of the drug as an initial treatment for triple-negative breast cancer patients who do not express PD-L1.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
3 hours ago
- Business Insider
Immatics announces presentation of data from ongoing Phase 1b trial on IMA203
Immatics (IMTX) announced the presentation of expanded data from the ongoing Phase 1b clinical trial evaluating IMA203 PRAME cell therapy in heavily pretreated patients with metastatic melanoma. The longer follow-up of patients demonstrates a consistent and favorable tolerability profile as well as durable responses with a confirmed ORR of 56%. In addition, the Company provided details from a Trial in Progress poster on SUPRAME, the ongoing Phase 3 clinical trial evaluating IMA203 in patients with unresectable or metastatic cutaneous melanoma who have received prior treatment with a checkpoint inhibitor. The most frequent treatment-emergent adverse events were anticipated cytopenias associated with lymphodepletion. Expected and manageable cytokine release syndrome was mostly Grades 1 and 2, which is consistent with the mechanism of action. The expected median PFS in this post-checkpoint inhibitor patient population6 is 2-3 months, and the IMA203 Phase 1b data presented today at ASCO indicate a continued median PFS of greater than or equal to 6 months. Confident Investing Starts Here:
Yahoo
3 hours ago
- Yahoo
Exercise ‘better than drugs' to stop cancer returning after treatment, trial finds
Exercise can reduce the risk of cancer patients dying by a third, stop tumours coming back and is even more effective than drugs, according to the results of a landmark trial that could transform health guidelines worldwide. For decades, doctors have recommended adopting a healthy lifestyle to lower the risk of developing cancer. But until now there has been little evidence of the impact it could have after diagnosis, with little support for incorporating exercise into patients' routines. Now a world-first trial involving patients from the US, UK, Australia, France, Canada and Israel has found that a structured exercise regime after treatment can dramatically reduce the risk of dying, the disease returning or a new cancer developing. The results were presented in Chicago at the American Society of Clinical Oncology (Asco) annual meeting, the world's largest cancer conference, and published in the New England Journal of Medicine. For the first time in medical history, there was clear evidence that exercise was even better at preventing cancer recurrence and death than many of the drugs currently prescribed to patients, one of the world's top cancer doctors said. Dr Julie Gralow, the chief medical officer of Asco, who was not involved in the decade-long study, said the quality of its findings was the 'highest level of evidence' and would lead to 'a major shift in understanding the importance of encouraging physical activity during and after treatment'. Patients who began a structured exercise regime with the help of a personal trainer or health coach after they completed treatment had a 37% lower risk of death and a 28% lower risk of recurrent or new cancers developing, compared with patients who received only health advice, the trial found. Asked to put the effect of exercise on cancer patients' outcomes into context, Gralow said: 'We titled [the session it was presented in] As Good as a Drug. I would have retitled it Better than a Drug, because you don't have all the side-effects.' 'It's the same magnitude of benefit of many drugs that get approved for this kind of magnitude of benefit – 28% decreased risk of occurrence, 37% decreased risk of death. Drugs get approved for less than that, and they're expensive and they're toxic.' 'When I started three decades ago it was still the era where we'd be gentle and say, don't overdo yourself when you're on chemo. We've reversed that,' she added. 'I would say [exercise is] better than a drug.' Related: Bowel cancer rising among under-50s worldwide, research finds In the trial, researchers enrolled 889 colon cancer patients between 2009 and 2023. Most (90%) had stage three disease. Patients were randomly assigned to take part in a structured exercise programme (445) or to just receive a healthy lifestyle booklet (444). Those in the exercise group worked with a personal trainer twice a month for coaching sessions and supervised exercise sessions, and later once a month, for a total of three years. The exercise group were coached and supported to help them achieve set exercise goals. Their weekly target was the equivalent of three to four walks of between 45 and 60 minutes, but patients could choose how they got more active. Some went kayaking or skiing, for instance. After five years, patients in the exercise group had a 28% lower risk of recurrent or new cancers than those in the other group. After eight years, the same patients also had a 37% lower risk of dying than those just handed the healthy lifestyle booklet. 'After completing surgery and chemotherapy, about 30% of patients with high-risk stage two and stage three colon cancer will eventually experience recurrence of their disease,' said the study's lead author, Dr Christopher Booth, of Queen's University in Kingston, Canada. 'As oncologists, one of the most common questions we get asked by patients is 'what else can I do to improve my outcome?' 'These results now provide us with a clear answer: an exercise programme that includes a personal trainer will reduce the risk of recurrent or new cancer, make you feel better and help you live longer.' Prof Charles Swanton, the chief clinician of Cancer Research UK, which funded the UK arm of the study, said: 'This fascinating study captures the power of exercise to transform people's health and boost their chances of surviving cancer after treatment. For an intervention that isn't a drug, exercise offers remarkable benefits for patients.' Related: Early morning and evening activity could 'reduce bowel cancer risk by 11%' For some patients, 'physical activity can be a gamechanger that shifts the course of their recovery', Swanton added. 'The findings suggest that oncologists should consider recommending a structured exercise programme after surgery to improve people's chances of survival. 'But it's important to remember that exercise isn't the best option for everyone. My advice to cancer patients is to speak to your doctor before taking on any new physical activity.' The findings are likely to change global practice, with doctors worldwide urged to discuss exercise regimens with their patients following treatment, oncologists in Chicago said. While this study followed only colon cancer patients, Gralow said there was no reason to think the findings would not be applicable across other cancers. Booth said trials for other cancers would be needed, but added that data from this study suggested there were lower breast and prostate cancer occurrences in the exercise group. 'Exercise as an intervention is a no-brainer and should be implemented broadly,' said Dr Pamela Kunz, of Yale School of Medicine. Responding to the findings, Prof Sir Stephen Powis, the national medical director of NHS England, said it was 'really exciting' that tailored exercise after treatment could be 'life-changing'. 'These landmark findings suggest that focused steps to exercise, from walks to workouts, could help turbocharge the body's ability to prevent cancer returning after treatment and help save more lives. 'Being more active can have significant benefits in helping maintain a healthy weight, strengthen the immune system, reduce inflammation and lift mood – and it's now really encouraging to see that exercise really could have the power to help more people survive cancer.'
Business Insider
4 hours ago
- Business Insider
Merck announces data from trial studying KEYTRUDA plus Trodelvy
Merck (MRK), known as MSD outside of the United States and Canada, announced that KEYTRUDA plus Trodelvy reduced the risk of disease progression or death by 35% versus KEYTRUDA plus chemotherapy for the first-line treatment of patients with PD-L1+ inoperable locally advanced or metastatic triple-negative breast cancer, TNBC, as determined by an FDA-approved test. KEYTRUDA, when given in combination with Gilead's TROP2 antibody-drug conjugate, ADC, Trodelvy, resulted in a median progression-free survival, PFS, of 11.2 months versus 7.8 months when KEYTRUDA was given in combination with chemotherapy. These data from the pivotal Phase 3 ASCENT-04/KEYNOTE-D19 study will be presented today as a late-breaking oral presentation at the 2025 American Society of Clinical Oncology, ASCO, Annual Meeting and were selected for the official ASCO Press Program. A higher objective response rate was observed for the KEYTRUDA plus Trodelvy combination, including 13% and 8% with a complete response, respectively, in the KEYTRUDA plus Trodelvy and KEYTRUDA plus chemotherapy arms. Notably, a substantially longer duration of response was observed with KEYTRUDA plus Trodelvy. Encouraging trends in overall survival were also observed, but data are immature at the time of PFS primary analysis. Overall survival follow-up remains ongoing and will continue to be monitored as a key secondary endpoint.
